Consensus Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
104.85 ^USD	+2.03%		+2.95%	+2.65%

01-22	Guardant Health Receives FDA Approval for Colorectal Cancer Diagnostic	MT
01-19	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI

Evolution of the Average Target: Guardant Health, Inc.

Evolution of the Target Price: Guardant Health, Inc.

Changes in Analyst Recommendations: Guardant Health, Inc.

bb69617bdefd7e816e932de8.l0t0p1wXNhERsJ6pE1lyIQhzNd6ZfABk6edEjO9UVQ8.ozg3yQt8UHhEgajMeBE6W2kDb5XhN0RRp9YFxJs8BWfwfkaebk1OaUTA-Q~7e01ba4aec814b441e93a1c7d9344816

Analysts' recommendations: Guardant Health, Inc.

29/09/25	Guardant Health Says US FDA Approves its Blood Test as Companion Diagnostic for Eli Lilly's Inluriyo	MT
25/09/25	Guardant Health Shares Rise After Wolfe Upgrade	MT
01/05/25	UBS Adjusts Guardant Health Price Target to $70 From $65, Maintains Buy Rating	MT
14/04/25	BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating	MT
10/04/25	Mizuho Initiates Guardant Health at Outperform	MT
05/03/25	Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating	MT
23/01/25	Barclays Initiates Guardant Health at Overweight	MT
26/08/24	Nephron Research Downgrades Guardant Health to Sell From Hold, $23 Price Target	MT
21/08/24	UBS Raises Price Target on Guardant Health to $40 From $32, Maintains Buy Rating	MT
28/06/24	Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36	MT
04/06/24	Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating	MT
03/06/24	Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target	MT
29/04/24	Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating	MT
15/04/24	Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	MT
26/02/24	Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating	MT
23/02/24	UBS Adjusts Guardant Health Price Target to $32 From $45, Maintains Buy Rating	MT
23/02/24	Canaccord Genuity Adjusts Price Target on Guardant Health to $45 From $50, Maintains Buy Rating	MT
29/01/24	Goldman Sachs Cuts Price Target on Guardant Health to $37 From $43, Maintains Buy Rating	MT
13/11/23	Raymond James Upgrades Guardant Health to Outperform From Market Perform, Price Target is $27	MT
23/10/23	Goldman Sachs Cuts Price Target on Guardant Health to $45 From $52, Keeps Buy Rating	MT
20/10/23	BofA Securities Adjusts Price Target on Guardant Health to $46 From $57, Maintains Buy Rating	MT
28/09/23	Bernstein Starts Guardant Health With Outperform Rating	MT
08/08/23	UBS Adjusts Guardant Health Price Target to $44 From $43, Maintains Buy Rating	MT
07/08/23	Morgan Stanley Adjusts Guardant Health's Price Target to $55 From $60, Keeps Overweight Rating	MT
26/05/23	Citigroup Upgrades Guardant Health to Buy From Neutral, Adjusts Price Target to $40 From $28	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GUARDANT HEALTH, INC.					+21.87%
	BIOMÉRIEUX					+28.36%
	SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.					+35.02%
	CARIS LIFE SCIENCES, INC.					+83.48%
	DIASORIN S.P.A.					+7.67%
	LANTHEUS HOLDINGS, INC.					+23.13%
	AUTOBIO DIAGNOSTICS CO., LTD.					+22.64%
	10X GENOMICS, INC.					+3.24%
	Average					+28.18%
	Weighted average by Cap.					+29.88%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

104.85USD

Average target price

125.24USD

Spread / Average Target

+19.45%

High Price Target

175.00USD

Spread / Highest target

+66.91%

Low Price Target

60.00USD

Spread / Lowest Target

-42.78%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Morgan Stanley
Wolfe Research
BofA Securities
Mizuho Securities
Barclays
Canaccord Genuity
Jefferies & Co.
Goldman Sachs
Piper Sandler
Raymond James
Bernstein
Citigroup
Credit Suisse
Scotiabank
Cowen
BTIG
JPMorgan Chase
Stephens Inc.
Craig-Hallum
SVB Leerink
Stifel Nicolaus
Wells Fargo Securities